Shilpa Medicare Limited has announced the appointment of Dr. Vellaian Karuppiah as the Chief Operating Officer (COO) – Formulations, effective April 23, 2026. With over 33 years of experience in the pharmaceutical industry, Dr. Karuppiah will lead the company’s formulations business. His appointment is aimed at driving operational excellence, strengthening supply chain resilience, and supporting the company’s long-term sustainable growth strategy.
Strategic Leadership Expansion
Shilpa Medicare Limited has strengthened its leadership team with the appointment of Dr. Vellaian Karuppiah as the new Chief Operating Officer (COO) for Formulations. The appointment became effective on April 23, 2026. Dr. Karuppiah brings a wealth of expertise to the role, having held C-suite positions at prominent pharmaceutical organizations including Gland Pharma Limited, Strides Group, Dr. Reddy’s Laboratories, and Actavis (now Teva).
Industry Expertise and Background
With a career spanning more than 33 years, Dr. Karuppiah possesses deep technical and managerial knowledge across the entire pharmaceutical value chain. His core competencies include Formulation & Analytical R&D, Regulatory Affairs, Manufacturing Science & Technology (MS&T), and Supply Chain Management. He holds a postgraduate degree and a Doctorate in Pharmacy, complemented by executive management qualifications from top-tier institutions.
Future Impact on Operations
In his new capacity, Dr. Karuppiah is expected to play a pivotal role in enhancing the company’s manufacturing efficiencies and R&D integration. His track record in delivering operational excellence and leading business transformation initiatives is anticipated to significantly bolster the company’s competitive position in the global market. The leadership at Shilpa Medicare expects this appointment to be a key driver for the firm’s long-term sustainable growth and overall organizational success.
Source: BSE
